Navigation Links
Archemix Announces Completion of Phase 1 Trial of ARC1779

rial blockage."

"We are developing a pipeline of aptamer therapeutics with a proprietary focus in acute cardiovascular and hematological diseases," commented Errol De Souza, Ph.D., President and Chief Executive Officer, Archemix. "The advancement of ARC1779 into Phase 2 will be a key milestone in the development of our broad product portfolio."

About Aptamers

Aptamers are single-stranded nucleic acids that form well-defined three dimensional shapes, allowing them to bind target molecules in a manner that is conceptually similar to antibodies. Aptamers combine the optimal characteristics of small molecules and antibodies, including high specificity and affinity, chemical stability, low immunogenicity and the ability to target protein-protein interactions. In contrast to monoclonal antibodies, aptamers are chemically synthesized rather than biologically expressed.

About Archemix

Archemix Corp. is a privately-held biopharmaceutical company developing aptamers as a class of directed therapeutics for the prevention and treatment of human disease. The company is leveraging its proprietary drug discovery technology to fuel the growth of its development portfolio, which is primarily focused on acute cardiovascular and hematology diseases and cancer. Archemix's broad product pipeline, being developed both by the company as well as its licensees, includes multiple investigational compounds at various stages of development, several of which are moving into Phase 2 clinical trials. Archemix's lead proprietary product, ARC1779, a selective platelet inhibitor, is anticipated to start a Phase 2a and Phase 1b clinical trial before the end of 2007. Archemix' leadership position in intellectual property, technology and expertise relating to aptamers has enabled it to form numerous collaborations with biotechnology and pharmaceutical collaborators, including Merck Serono, Pfizer Inc., Elan Pharma, Nuvelo, Inc., Antisoma plc., and Regado Biosciences.
'"/>




Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Archemix Announces Completion Phase Trial ARC1779
(Date:7/28/2014)... , July 28, 2014 ... investing £2.5 million to help it meet the ... goods, healthcare, pharmaceuticals and logistics. Albion joins Shackleton ... ) Over the past 18 months ... its platform, its management team and its operations. ...
(Date:7/25/2014)... 25, 2014  Depomed, Inc. (NASDAQ: DEPO ... fiscal year 2014 financial results after the market closes ... conference call beginning at 4:30 pm EDT, 1:30 pm PDT to ... call by dialing 877-317-6789 ( United States ... be available via a live webcast on the investor ...
(Date:7/25/2014)... 2014 GrowBLOX Sciences, Inc. (OTCQB: GBLX) is pleased ... ("MOU") with LaurelCo, LLC, an Illinois ... cultivation and dispensary medical marijuana licenses in the state of ... will acquire a 20% equity interest in LaurelCo, LLC in ... growing chambers, as well as all technology related to the ...
Breaking Medicine Technology:OmPrompt Funded for Customer Automation Management Market Expansion 2Depomed To Report Second Quarter Fiscal Year 2014 Financial Results On Wednesday, August 6, 2014 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 2GrowBLOX Sciences, Inc. Partners with LaurelCo, LLC to Obtain Licenses to Cultivate and Dispense Medical Marijuana in Illinois 3
... FALLS, N.J., Aug. 31, 2011 CANTEL MEDICAL CORP. ... A. Krakauer, President & CEO, will be presenting at the ... is scheduled for 11:15 AM EDT on Tuesday, September 13, ... City, with a Q & A session immediately following the ...
... Prix Galien USA Committee, responsible for awarding the most ... that Dr. Paul Farmer will be awarded the 2011 ... Galien USA Award Ceremony.  The annual award presentation accompanies ... made innovative contributions to biopharmaceutical and medical technology research ...
Cached Medicine Technology:Dr. Paul Farmer Selected as 2011 Pro Bono Humanum Honoree by Prix Galien USA 2
(Date:7/28/2014)... Top Northridge dentist , Dr. Farshid Ariz, is ... new dentist can be an intimidating experience. Many people struggle ... and worry about how they will connect with a new ... concerns and dental needs and works to ensure that each ... special coupon can help patients get the treatments they need ...
(Date:7/28/2014)... Freeonlinelifeinsuranceleads.com has released a new blog ... insurance quotes. , Comparing life insurance quotes can help ... costs. Finding affordable coverage is easier online by visiting ... agencies and displays them on a single web page. ... find cheaper coverage, but they can also learn more ...
(Date:7/28/2014)... (HealthDay News) -- Following a healthy lifestyle may help ... issues, a new study indicates. Researchers suggested that ... should be educated about how their diet ... future. "These findings are important because they indicate ... have the opportunity to influence their own health outcomes," ...
(Date:7/28/2014)... Nevada (PRWEB) July 28, 2014 Mahendra ... Trivedi, hosted the Trivedi Online Workshop ‘Consciousness is Power’ ... PM (EST). During this workshop, participants from all over ... importance of making a deeper connection to their inner ... the participants explored the various advantages of raising consciousness ...
(Date:7/28/2014)... 28, 2014 Alta Resources , ... (BPO) for Fortune 500 brands, announced today that it ... locations in Wisconsin, California, Florida and the Philippines. More ... its Fort Myers campus, and the company announced that ... is to support several health-insurance clients, which have seasonal ...
Breaking Medicine News(10 mins):Health News:Northridge Dentist, Dr. Farshid Ariz, is Now Offering a $100 Coupon for New Patients 2Health News:Comparing Life Insurance Quotes Online Offers 3 Important Advantages! 2Health News:Healthy Habits May Help Childhood Cancer Survivors Avoid Chronic Ills 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 2Health News:Trivedi Online Workshop ‘Consciousness is Power’ was Huge Success 3Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 2Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 3Health News:Alta Resources To Fill Approximately 1,200 Positions In Fort Myers 4
... Hospitals (UH) Case Medical Center is conducting the first ... "heat therapy" or local radiofrequency energy to treat premature ... to the energy produced by radio waves directed with ... a nerve. Premature ejaculation (PE) affects 20 percent ...
... Research Institute (LRI) today announced the award of 12 ... drive innovation and discover novel approaches to understand and ... diseases lupus. Awarded for the highest-ranked ... topics and multi-disciplinary approaches that mirror the heterogeneity and ...
... Institute (GHI) and Inserm (Institut National de la Sant ... for biomedical research) has discovered that a class of ... in cancer cells also kills the parasite that causes ... new strategy for combating this deadly disease. The ...
... leg ulcers is good quality nursing care and the ... University of Leeds has shown that ultrasound therapy does nothing ... contrary to what had been expected. Traditional methods of nursing ... as well, the authors conclude. "The ,healing energy, of ...
... might be required for maximum anti-tumor activity when ... studies by Vanderbilt-Ingram Cancer Center (VICC) investigators. The ... Proceedings of the National Academy of Sciences ... HER3 receptor limits the effectiveness of two classes ...
... An analysis conducted by Ohio State University cancer ... to the treatment of patients with advanced ovarian cancer ... value of various clinical strategies will be published online ... , The researchers performed a cost-effectiveness analysis looking at ...
Cached Medicine News:Health News:University Hospitals Case Medical Center testing innovative 'heat therapy' for premature ejaculation 2Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 2Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 3Health News:LRI awards wide-ranging research grants to drive next generation of scientific discovery in lupus 4Health News:Malaria's weakest link 2Health News:Laughter really is the best medicine (for leg ulcers) 2Health News:Hit multiple targets for maximum benefit in HER2-positive breast cancer, studies suggest 2Health News:Ohio State study: Targeted ovarian cancer therapy not cost-effective 2Health News:Ohio State study: Targeted ovarian cancer therapy not cost-effective 3
The ABL77 is always ready to use. No manual cassette preparation or calibration necessary prior to testing. Portable with battery. For both high and low volume testing....
348 is fully automated blood gas systems offering a cost-effective solution for critical care testing in settings with low to medium workloads....
The AVL Omni modular system is a complete blood gas solution designed for high-volume critical care use, with customized test combinations, minimum intervention and flexibility....
... optimal combination of performance and rapid, ... mL swinging bucket rotor. DiscoveryTMM120 SE ... to 8.3 ml, with a small ... quiet operation, rotor imbalance detection, thermo-electric ...
Medicine Products: